Latest News
NextNRG Revenue Climbs 29% but Cash Warning Looms
NextNRG's Q1 revenue surged 29% to $21.1M, but a widening net loss and cash crunch raise doubts about its ability to continue operations without new funding.
HCW Biologics Surges 262% on Trimmune Deal and Profit, Nasdaq Risk Looms
HCW Biologics shares jumped 262% after a licensing deal with Beijing Trimmune Biotech fueled a Q1 profit. The company still faces Nasdaq delisting risks and will seek shareholder approval for a reverse stock split.
Bank of America $2.25M 7-Eleven ATM Fee Settlement: Claim Deadline June 29
Bank of America settles claims of duplicate ATM fees at 7-Eleven for $2.25 million. Former clients have until June 29 to file claims.
SpaceX Accelerates Nasdaq IPO to Mid-June, Targeting $1.75 Trillion Valuation
SpaceX aims to list on Nasdaq by June 12 under ticker SPCX, seeking $75 billion at a $1.75 trillion valuation. The IPO includes supervoting shares and strict shareholder limits.
Broadcom Leads AI Chip Slide as Inflation Fears Resurface
Broadcom shares dropped 3.3% on Friday, leading a broad decline in AI chip stocks as rising oil prices and Treasury yields reignited inflation fears.
GCT Semiconductor Faces Scrutiny Over 5G Ramp-Up and Cash Concerns
TD Securities reveals a 4.6% beneficial ownership in GCT Semiconductor, primarily via deep out-of-the-money warrants. The company's 5G chipset shipments rose 58% but revenue remains modest, and liquidity concerns persist.
Tonix Pharma Surges on Promising Lyme Antibody Data; Phase 2 Trial Eyed for 2027
Tonix Pharmaceuticals shares rose after new Phase 1 modeling data for its Lyme antibody TNX-4800 showed six-month protection with two doses. A Phase 2 trial is targeted for 2027.
AXT Reschedules Annual Meeting After Quorum Failure
AXT adjourned its 2026 annual meeting after failing to reach a quorum, rescheduling for June 4. The company seeks shareholder approval to raise authorized shares.
Hyperscale Data Surges on $5M Tender Offer; 10-Q Filing in Focus
Hyperscale Data (GPUS) jumps on $5M tender offer at $0.21/share, as Q1 preliminary results show $44M revenue and $30M net loss. The delayed 10-Q filing is the next catalyst.